Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Capital Expenditures (2017 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Capital Expenditures for 5 consecutive years, with $431.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures changed N/A year-over-year to $431.0, compared with a TTM value of -$44600.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $6256.0, changed N/A over the prior year.
  • Capital Expenditures was $431.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$45031.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $58119.0 in Q1 2021 and bottomed at -$45031.0 in Q4 2024.
  • Average Capital Expenditures over 3 years is $4816.2, with a median of $3088.5 recorded in 2021.